{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T13:08:28Z","timestamp":1759410508642},"reference-count":32,"publisher":"American Society for Microbiology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Vaccine Immunol."],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The cell-based anthrax toxin neutralization assay (TNA) is used to determine functional antibody titers of sera from animals and humans immunized with anthrax vaccines. The anthrax lethal toxin is a critical reagent of the TNA composed of protective antigen (PA) and lethal factor (LF), which are neutralization targets of serum antibodies. Cytotoxic potency of recombinant LF (rLF) lots can vary substantially, causing a challenge in producing a renewable supply of this reagent for validated TNAs. To address this issue, we characterized a more potent rLF variant (rLF-A) with the exact native LF amino acid sequence that lacks the additional N-terminal histidine and methionine residues present on the commonly used form of rLF (rLF-HMA) as a consequence of the expression vector. rLF-A can be used at 4 to 6 ng\/ml (in contrast to 40 ng\/ml rLF-HMA) with 50 ng\/ml recombinant PA (rPA) to achieve 95 to 99% cytotoxicity. In the presence of 50 ng\/ml rPA, both rLF-A and rLF-HMA allowed for similar potencies (50% effective dilution) among immune sera in the TNA. rPA, but not rLF, was the dominant factor in determining potency of serum samples containing anti-PA antibodies only or an excess of anti-PA relative to anti-rLF antibodies. Such anti-PA content is reflected in immune sera derived from most anthrax vaccines in development. These results support that 7- to 10-fold less rLF-A can be used in place of rLF-HMA without changing TNA serum dilution curve parameters, thus extending the use of a single rLF lot and a consistent, renewable supply.<\/jats:p>","DOI":"10.1128\/cvi.00046-13","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T07:54:35Z","timestamp":1367481275000},"page":"986-997","source":"Crossref","is-referenced-by-count":2,"title":["Characterization of the Native Form of Anthrax Lethal Factor for Use in the Toxin Neutralization Assay"],"prefix":"10.1128","volume":"20","author":[{"given":"Hang","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Catania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katalin","family":"Baranji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mili","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Lathey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Sweeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kavita","family":"Sapru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Patamawenu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June-Home","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenbework","family":"Fesseha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Kluepfel-Stahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Minang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Alleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","published-online":{"date-parts":[[2013,5,1]]},"reference":[{"key":"key20180919073659_B1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.mam.2009.06.002","article-title":"Anthrax toxins: a weapon to systematically dismantle the host immune defenses","volume":"30","author":"Tournier","year":"2009","journal-title":"Mol. Aspects Med."},{"key":"key20180919073659_B2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.mam.2009.07.003","article-title":"Cellular and systemic effects of anthrax lethal toxin and edema toxin","volume":"30","author":"Moayeri","year":"2009","journal-title":"Mol. Aspects Med."},{"key":"key20180919073659_B3","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.micinf.2011.12.005","article-title":"Anthrax and the inflammasome","volume":"14","author":"Moayeri","year":"2012","journal-title":"Microbes Infect."},{"key":"key20180919073659_B4","doi-asserted-by":"publisher","first-page":"e1002638","DOI":"10.1371\/journal.ppat.1002638","article-title":"Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome","volume":"8","author":"Levinsohn","year":"2012","journal-title":"PLoS Pathog."},{"key":"key20180919073659_B5","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.mam.2009.08.006","article-title":"Anthrax vaccination strategies","volume":"30","author":"Cybulski","year":"2009","journal-title":"Mol. Aspects Med."},{"key":"key20180919073659_B6","doi-asserted-by":"crossref","first-page":"D28","DOI":"10.1016\/j.vaccine.2009.08.102","article-title":"Advances in the development of next-generation anthrax vaccines","volume":"27","author":"Friedlander","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073659_B7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1128\/CVI.05556-11","article-title":"Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis","volume":"19","author":"Bellanti","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073659_B8","first-page":"1","article-title":"Use of anthrax vaccine in the United States; recommendation of the Advisory Committee on Immunization Practices, 2009","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"key20180919073659_B9","article-title":"Guidance for industry; animal models\u2013essential elements to address efficacy under the animal rule","author":"U. S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research","year":"2009"},{"key":"key20180919073659_B10","doi-asserted-by":"publisher","first-page":"151ra126","DOI":"10.1126\/scitranslmed.3004073","article-title":"Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge","volume":"4","author":"Fay","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"key20180919073659_B11","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1016\/j.vaccine.2011.03.011","article-title":"Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity","volume":"29","author":"Crowe","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073659_B12","doi-asserted-by":"crossref","first-page":"6089","DOI":"10.1016\/j.vaccine.2007.05.018","article-title":"Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine","volume":"25","author":"Hepburn","year":"2007","journal-title":"Vaccine"},{"key":"key20180919073659_B13","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1016\/j.vaccine.2012.03.002","article-title":"Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization","volume":"30","author":"Smith","year":"2012","journal-title":"Vaccine"},{"key":"key20180919073659_B14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1128\/CVI.00321-07","article-title":"Neutralizing activity of vaccine-induced antibodies to two Bacillus anthracis toxin components, lethal factor and edema factor","volume":"15","author":"Taft","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073659_B15","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1128\/CVI.00003-08","article-title":"Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species","volume":"15","author":"Omland","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073659_B16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1365-2672.1999.00897.x","article-title":"In vitro correlate of immunity in an animal model of inhalational anthrax","volume":"87","author":"Pitt","year":"1999","journal-title":"J. Appl. Microbiol."},{"key":"key20180919073659_B17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"key":"key20180919073659_B18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"},{"key":"key20180919073659_B19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"key20180919073659_B20","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1128\/CVI.00145-10","article-title":"Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays","volume":"17","author":"Brady","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073659_B21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1128\/CVI.00267-10","article-title":"Reduction of immunogenicity of anthrax vaccines subjected to thermal stress, as measured by a toxin neutralization assay","volume":"18","author":"Castelan-Vega","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073659_B22","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1128\/IAI.00368-09","article-title":"The case for developing consensus standards for research in microbial pathogenesis: Bacillus anthracis toxins as an example","volume":"77","author":"Hughes","year":"2009","journal-title":"Infect. Immun."},{"key":"key20180919073659_B23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/CVI.00513-09","article-title":"Comparison of three anthrax toxin neutralization assays","volume":"17","author":"Ngundi","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073659_B24","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1016\/j.vaccine.2009.05.045","article-title":"Comparability of ELISA and toxin neutralization to measure immunogenicity of protective antigen in mice, as part of a potency test for anthrax vaccines","volume":"27","author":"Parreiras","year":"2009","journal-title":"Vaccine"},{"key":"key20180919073659_B25","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1128\/CVI.00081-08","article-title":"Role of the N-terminal amino acid of Bacillus anthracis lethal factor in lethal toxin cytotoxicity and its effect on the lethal toxin neutralization assay","volume":"15","author":"Verma","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"key20180919073659_B26","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1006\/prep.2000.1208","article-title":"Optimized production and purification of Bacillus anthracis lethal factor","volume":"18","author":"Park","year":"2000","journal-title":"Protein Expr. Purif."},{"key":"key20180919073659_B27","doi-asserted-by":"publisher","first-page":"e3130","DOI":"10.1371\/journal.pone.0003130","article-title":"Role of N-terminal amino acids in the potency of anthrax lethal factor","volume":"3","author":"Gupta","year":"2008","journal-title":"PLoS One"},{"key":"key20180919073659_B28","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"key":"key20180919073659_B29","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1146\/annurev.biochem.75.103004.142728","article-title":"Anthrax toxin: receptor binding, internalization, pore formation, and translocation","volume":"76","author":"Young","year":"2007","journal-title":"Annu. Rev. Biochem."},{"key":"key20180919073659_B30","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1021\/bi015860m","article-title":"Stoichiometry of anthrax toxin complexes","volume":"41","author":"Mogridge","year":"2002","journal-title":"Biochemistry"},{"key":"key20180919073659_B31","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3390\/toxins3081004","article-title":"Monoclonal antibody therapies against anthrax","volume":"3","author":"Chen","year":"2011","journal-title":"Toxins (Basel)"},{"key":"key20180919073659_B32","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1128\/IAI.00261-07","article-title":"Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax","volume":"75","author":"Albrecht","year":"2007","journal-title":"Infect. Immun."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1128\/CVI.00046-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:49:20Z","timestamp":1627591760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00046-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,1]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2013,6,25]]},"published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1128\/CVI.00046-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00046-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,1]]}}}